Expertise in
42
conditions

Dr. David Sallman

Hematology | Oncology
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
42
conditions
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

David Sallman is a Hematologist and an Oncologist in Tampa, Florida. Dr. Sallman is highly rated in 42 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sallman is currently accepting new patients.

His clinical research consists of co-authoring 205 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of South Florida College Of Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Sallman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Adult Immune Thrombocytopenia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drug: CLN-049
Study Phase: Phase 1
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
Phase 1/1b Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: January 07, 2026
Intervention Type: Drug
Study Drug: Minnelide
Study Phase: Phase 1
A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Phase: Phase 2
Development of a Quality of Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia
Development of a Quality of Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2025
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
Enrollment Status: Completed
Publish Date: November 04, 2025
Intervention Type: Drug, Biological
Study Drug: CD8-Depleted Donor Lymphocyte Infusion
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Drug
Study Drugs: Canakinumab, Darbepoetin Alfa
Study Phase: Phase 1/Phase 2
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Procedure, Drug
Study Drugs: Daunorubicin, Cytarabine
Study Phase: Phase 1
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome
A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drug: PRGN-3006 T Cells
Study Phase: Phase 1
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: APR-246, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: October 12, 2021
Intervention Type: Drug
Study Drug: AMV564 Bispecific CD33/CD3 T Cell Engager
Study Phase: Phase 1
An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.
An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Biological
Study Drugs: NKR-2 NKG2D-Positive Modified Natural Killer T Cells, Cyclophosphamide, Fludarabine
Study Phase: Phase 1/Phase 2
A Phase 1 Study of Lenzilumab in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)
A Phase 1 Study of Lenzilumab in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: February 28, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

205 Total Publications

Menin inhibitors for adult acute myeloid leukemia: 2025 update.
Menin inhibitors for adult acute myeloid leukemia: 2025 update.
Journal: Expert opinion on investigational drugs
Published: December 31, 2025
Similar Doctors
Expertise in
41
conditions
Dr. Andrew Kuykendall
Hematology | Oncology
Expertise in
41
conditions
Dr. Andrew Kuykendall
Hematology | Oncology

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-701-3769
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Kuykendall is a Hematologist and an Oncologist in Tampa, Florida. Dr. Kuykendall is highly rated in 41 conditions, according to our data. His top areas of expertise are Myelofibrosis, Polycythemia Vera, Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), and Bone Marrow Aspiration. Dr. Kuykendall is currently accepting new patients.

Expertise in
34
conditions
Dr. Bijal Shah
Hematology | Oncology
Expertise in
34
conditions
Dr. Bijal Shah
Hematology | Oncology

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-820-1873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bijal Shah is a Hematologist and an Oncologist in Tampa, Florida. Dr. Shah is highly rated in 34 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Shah is currently accepting new patients.

Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-692-4147
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist in Tampa, Florida. Dr. Sokol is highly rated in 55 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Frequently Asked Questions about Dr. David Sallman

How do I make an appointment with Dr. David Sallman?

You can book an appointment with Dr. David Sallman by calling their office at 813-566-0117. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David Sallman a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David Sallman is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David Sallman specialize in?

While Dr. David Sallman is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Chronic Myelomonocytic Leukemia (CMML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. David Sallman participate in research or clinical trials?

Yes. Dr. David Sallman has published 205 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. David Sallman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David Sallman accept my insurance?

Dr. David Sallman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-566-0117 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sallman's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 27 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile